THRB (Thyroid Hormone Receptor beta) Drug Discovery Landscape & Assay Solutions
- By admin
- 05 Aug 2026
- Comments
Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for MASH/NASH and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for THRB drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | THRB Recombinant Protein (LBD & DBD Constructs; WT and mutants available). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Custom GRTHD-associated mutants (e.g., R243Q, R320C) available. Suitable for TR-FRET, SPR, and coactivator recruitment assays. | View THRB Products |
| Isoform Selectivity Panel | THRA (NR1A1) LBD Recombinant Protein (Human/Mouse/Cyno). For counter-screening and selectivity ratio determination against cardiac isoform. High purity, sequence verified, HEK293 expressed. | View THRA Products |
| Gene Delivery | THRB Promise-ORF / Lentivirus. Full-length THRB ORF for stable cell line generation (e.g., HepG2, Huh7) and transactivation reporter assays. Puromycin selection marker. | View THRB Products |
| Benchmark Ab | Anti-THRB (Recombinant Rabbit mAb). ChIP/ICC/WB-grade positive control for target engagement and localization studies. | View THRB Products |
| Validator | THRB siRNA Set. Three unique target sequences for knockdown verification in functional assays. | View THRB Products |
| Related Target A | THRA (NR1A1). Isoform selectivity counter-screen to eliminate cardiotoxic thyromimetic off-targets. | View THRA Products |
| Related Target B | RXRA. Obligate heterodimer partner required for functional THRB DNA-binding and coactivator recruitment assays. | View RXRA Products |
| Related Target C | FGF21. Downstream marker of THRB activation; complementary pathway for combination NASH studies. | View FGF21 Products |
| Related Target D | THRSP (Thyroid Hormone Responsive). Synergistic metabolic pathway target in lipogenesis. | View THRSP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| THRB vs THRA isoform selectivity profiling | Purified human THRB-LBD and THRA-LBD proteins, sequence verified, >95% purity, endotoxin controlled for parallel TR-FRET/SPR panels. Multiple species available. |
| Cell-based transactivation & reporter assays | THRB lentivirus particles for stable integration into HepG2 and Huh7 lines; MOI optimized for homogeneous reporter signal. |
| Orthogonal target validation & false-positive control | Matched anti-THRB recombinant antibody and validated siRNA for knockdown/rescue confirmation. |
| Co-activator recruitment quantification | High-concentration THRB-LBD protein suitable for TR-FRET and AlphaScreen assays with SRC-1/NCOA1 peptides. |
| Heterodimer functional assays | RXRA recombinant protein available for co-incubation and coactivator recruitment bridging assays. |
| Off-target activation artifacts | Endotoxin-controlled (<1 EU/μg) proteins to prevent LPS-mediated activation of NF-κB or other nuclear receptors causing false positives. |
Live THRB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for THRB therapeutics crossed a historic milestone with the March 2024 FDA approval of Resmetirom (Rezdiffra™) for metabolic dysfunction-associated steatohepatitis (MASH), marking the first approved drug for NASH and validating THRB as a druggable target. The competitive landscape has shifted from broad thyroid hormone analogs to highly isoform-selective thyromimetics with liver-targeted prodrug strategies. Current R&D emphasizes combination regimens with GLP-1 receptor agonists and FGF21 analogs to maximize fibrosis resolution while avoiding cardiac and bone off-targets mediated by THRA.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonist | Madrigal Pharmaceuticals (Resmetirom), Terns Pharma (TERN-501), Ascletis (ASC41) | MASH/NASH, Dyslipidemia | Selectivity TR-FRET/SPR (Need purified THRB-LBD vs THRA-LBD) |
| Liver-Targeted Prodrug | Viking Therapeutics (VK2809), Eli Lilly | MASH with high cardiovascular risk | Stable THRB Reporter Cell Lines (Need lentivirus-based transduction) |
| Combination Therapy | Madrigal + GLP-1R axis (investigational); Various Biopharma | Obesity, Advanced Fibrosis, Metabolic Syndrome | Pathway Reporter Assays (Need THRB ORF and metabolic gene panels) |
Key Mutations and Functional Domains
THRB, a nuclear receptor (NR1A2), contains a ligand-binding domain (LBD) critical for hormone-dependent transactivation. Clinically relevant mutations associated with Resistance to Thyroid Hormone beta (RTHβ) include:
- R243Q (rs9865746): Impairs hormone binding and ligand-dependent conformational changes.
- R320C (rs121918707): Also linked to GRTHD; reduces affinity for T3.
- Other GRTHD mutations (e.g., A234T, R438H) are catalogued in UniProt (P10828).
These mutations disrupt coactivator recruitment and DNA binding. TarMart offers custom recombinant THRB LBD proteins carrying these mutations for mechanistic studies and selectivity profiling.